



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	336202	L. Rhamnosus
ARTG entry for	Medicine Listed	
Sponsor	Spectrumceuticals Pty Ltd	
Postal Address	Unit 8/5 Narabang Way, BELROSE, NSW, 2085 Australia	
ARTG Start Date	12/05/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . L. Rhamnosus

Product Type	Single Medicine Product	Effective Date	11/03/2022
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Maintain/support general health and wellbeing
Decrease/reduce/relieve diarrhoea in children
Maintain/support intestinal health
Maintain/support intestinal good/beneficial/friendly flora
Maintain/support small intestine good/beneficial/friendly flora
Maintain/support gastrointestinal system health
Maintain/support gastrointestinal mucosal membrane health
Maintain/support immune system health
Maintain/support healthy immune system function
Maintain/support healthy gastrointestinal immune function

Indication Requirements

Product presentation must not imply or refer to serious immunological diseases.

Label statement: Seek medical advice if diarrhoea persists for more than: 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3 to 6 years or 48 hours in adults and children over 6 years (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If diarrhoea persists for more than 6 hours in infants under 6 months, 12 hours in children under 3 years, 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years, seek medical advice (or words to that effect).

Additional Product information

Pack Size/Poison information



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Lactobacillus rhamnosus 20 billion CFU

Other Ingredients (Excipients)

colloidal anhydrous silica

hypromellose

magnesium stearate

microcrystalline cellulose

potable water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary